As previously noted, CRV431 in particular was shown to be more effective in this regard than another candidate NAFLD drug, OCA, which is a farnesoid X receptor agonist and does not affect cyclophilins. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.